US FDA advisers return modern Covid-1 boo booster shots for the elderly and high-risk people by Reuters

স্বাস্থ্য Reuters file photo: A health worker holds a bottle of the modern Covid-1V vaccine at a pop-up vaccination site run by Somos Community Care during the coronavirus (Covid-1) epidemic in Manhattan, New York City, USA, January 29, 2021.

Written by Manas Mishra and Julie Steinhuisen

(Reuters) – A panel of expert advisers to the U.S. Food and Drug Administration unanimously voted Thursday to recommend a booster shot. Modern (NASDAQ 🙂 Inc.’s Covid-1 vaccine is for Americans 5 years of age or older and at high risk of serious illness or professional exposure to the virus.

If the FDA signs the Modern Booster, U.S. Centers for Disease Control and Prevention will make specific recommendations on who should get the shots. A meeting of CDC advisers is scheduled for next week.

The FDA’s Vaccine and Related Organic Products Advisory Committee met Thursday to consider additional doses of the modern vaccine and to consider a similar recommendation for the Johnson & Johnson (NYSE) vaccine on Friday. The vote to support Moderner Booster was 19-0.

Dr. University of Pittsburgh School of Medicine. “The data itself is not strong, but it is certainly moving in support of this vote,” said Patrick Moore. Moore said he voted for Modern Booster based primarily on “gut feelings rather than serious information.”

Shares of Modern rose nearly 3% to 30 330.71 after the vote.

In a document posted Tuesday, FDA officials said , Modern vaccine data show that booster boosts protective antibodies.

But they also said that the difference in antibody levels before and after the shot was not wide enough by a measure of success determined by the FDA, especially those who had high levels of antibodies.

Moderena is seeking approval for a booster that contains 50 micrograms of vaccine, half the strength of its regular dose but still more than Pfizer / Biotech shots using similar technology at 30 micrograms.

The booster will be given to humans at least six months after the initial two-shot inoculation.

U.S. health officials have been under pressure to approve the Covid-1 vaccine booster dose after the White House announced in August that it was planning a massive booster campaign awaiting FDA and CDC approval.

Both companies have signed Pfizer / BioNTech boosters at 09 -Last month for some high-risk adults. Since then, about 9 million people have received third shots, the CDC reported Wednesday.

The panel heard a presentation by Israeli health officials that Pfizer / Biotech vaccine supporters had helped prevent the latest wave of infections in their country.

In a presentation on Thursday, they said that the booster program in Israel has improved the protection of critically ill people aged 40 and over.

“What we’re seeing is a break in Israel’s epidemic curve,” said Dr. Shar Sharon Alroy-Press, director of public health services at Israel’s health ministry.

He said the booster program, which now covers 50% of the population of all ages, has also begun to reduce infections among unpublished people in Israel.

Boston Children’s Hospital vaccine specialist and panel member Dr. Offer Levy noted that the United States and Israel have different populations and that the vaccine used by Israel is different, though similar to the modern shot.

Dr. Hay Haley Gans, a pediatrician and panel member at Stanford University Medical Center, asked if the Israeli Ministry of Health could say how much of the country’s eroded delta waves were responsible for the booster program and how much could have happened without them.

“I have no question in my mind that the booster shot was responsible for changing the epidemic curve in Israel,” Alroy-Press replied.

In the U.S., DeltaGu has already begun to ease, with a seven-day average of daily COVID-19 cases down 12% compared to the previous week and a seven-day average of daily deaths down 5%. It still kills more than 1,250 Kovid-1 deaths a day, but initially among the obsolete.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button